DE69919179T2 - Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen - Google Patents

Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen Download PDF

Info

Publication number
DE69919179T2
DE69919179T2 DE69919179T DE69919179T DE69919179T2 DE 69919179 T2 DE69919179 T2 DE 69919179T2 DE 69919179 T DE69919179 T DE 69919179T DE 69919179 T DE69919179 T DE 69919179T DE 69919179 T2 DE69919179 T2 DE 69919179T2
Authority
DE
Germany
Prior art keywords
compound
mmol
mixture
added
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69919179T
Other languages
German (de)
English (en)
Other versions
DE69919179D1 (de
Inventor
Yaping Shen
L. David BURGOYNE
W. Ronald LAUENER
Yuanlin Zhou
J. Patrick REBSTEIN
D. Samuel ABRAHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolipox AB
Original Assignee
Inflazyme Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazyme Pharmaceuticals Ltd filed Critical Inflazyme Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE69919179D1 publication Critical patent/DE69919179D1/de
Publication of DE69919179T2 publication Critical patent/DE69919179T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69919179T 1998-09-09 1999-09-09 Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen Expired - Lifetime DE69919179T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9963798P 1998-09-09 1998-09-09
US99637P 1998-09-09
US12150799P 1999-02-23 1999-02-23
US121507P 1999-02-23
US14951799P 1999-08-17 1999-08-17
US149517P 1999-08-17
PCT/CA1999/000819 WO2000014083A1 (en) 1998-09-09 1999-09-09 SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO

Publications (2)

Publication Number Publication Date
DE69919179D1 DE69919179D1 (de) 2004-09-09
DE69919179T2 true DE69919179T2 (de) 2005-07-28

Family

ID=27378872

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69919179T Expired - Lifetime DE69919179T2 (de) 1998-09-09 1999-09-09 Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen

Country Status (9)

Country Link
US (1) US6458829B1 (enExample)
EP (1) EP1112262B1 (enExample)
JP (1) JP4979157B2 (enExample)
AT (1) ATE272628T1 (enExample)
AU (1) AU757052B2 (enExample)
CA (1) CA2343732C (enExample)
DE (1) DE69919179T2 (enExample)
ES (1) ES2226422T3 (enExample)
WO (1) WO2000014083A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770658B2 (en) * 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US9931318B2 (en) * 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US20040224316A1 (en) 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
KR100439425B1 (ko) * 2001-03-22 2004-07-05 (주)바이오케어 잔토리졸을 포함하는 조성물 및 그 용도
KR20040007583A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7642252B2 (en) * 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
EP2177626B1 (en) 2002-08-19 2013-12-18 Dart NeuroScience (Cayman) Ltd Screening methods for cognitive enhancers
ES2213485B1 (es) * 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
JP2007526460A (ja) * 2004-03-03 2007-09-13 バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法
WO2006086693A2 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
US20080171746A1 (en) * 2005-03-14 2008-07-17 Thomas Klein Method for Preventing Cardiovascular Diseases
EP2377533A3 (en) 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
AR065709A1 (es) * 2007-03-12 2009-06-24 Biolipox Ab Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion.
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms
CN103351390A (zh) * 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3607885A (en) * 1968-08-15 1971-09-21 Universal Oil Prod Co Preparation of lactones such as substituted delta valerolactones
US3644426A (en) * 1969-08-15 1972-02-22 Universal Oil Prod Co Preparation of delta valero-lactones
US3814771A (en) * 1970-11-19 1974-06-04 T Shen 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones
US3718743A (en) * 1970-11-19 1973-02-27 Merck & Co Inc 5-phenyl-2-piperidones and 5-phenyl-2-thiopiperidones in compositions and methods for treating pain, fever and inflammation
JPS51131870A (en) * 1975-01-20 1976-11-16 Yoshitomi Pharmaceut Ind Ltd A process for preparing novel amide compounds
JPS52156859A (en) * 1976-06-18 1977-12-27 Yoshitomi Pharmaceut Ind Ltd Heterocyclic amide derivatives
US4616089A (en) * 1983-08-03 1986-10-07 University Of California Synthetic anti-inflammatory derivatives of manoalide
JP3101053B2 (ja) * 1992-02-07 2000-10-23 株式会社共立 新規化合物及び該化合物を含有するマツノザイセンチュウ殺線虫剤
DE19603477A1 (de) * 1996-01-31 1997-08-07 Klaus Dr Med Reuter Tumormittel
KR20000070396A (ko) * 1997-01-22 2000-11-25 고토 기치 액정 화합물, 이를 함유하는 액정 조성물 및 이를 함유하는액정 디스플레이 장치

Also Published As

Publication number Publication date
JP4979157B2 (ja) 2012-07-18
CA2343732C (en) 2009-06-16
WO2000014083A1 (en) 2000-03-16
AU757052B2 (en) 2003-01-30
US6458829B1 (en) 2002-10-01
AU5500999A (en) 2000-03-27
EP1112262A1 (en) 2001-07-04
CA2343732A1 (en) 2000-03-16
ATE272628T1 (de) 2004-08-15
ES2226422T3 (es) 2005-03-16
JP2002524456A (ja) 2002-08-06
DE69919179D1 (de) 2004-09-09
EP1112262B1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
JP4979157B2 (ja) 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用
DE60036101T2 (de) Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren
DE69930619T2 (de) Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen
DE69431568T2 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
EP0142801B1 (en) Indene derivatives useful as paf-antagonists
EP3506894B1 (en) Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
DE69128627T2 (de) Tnf-inhibitoren
US6770658B2 (en) Substituted γ-phenyl-Δ-lactams and uses related thereto
US6911460B2 (en) Antiviral agents and methods of treating viral infections
DE69327153T2 (de) Anti-hiv-medikament
DE69808099T2 (de) Substituierte 6-alkylphenanthridine
DE69403063T2 (de) Gegen viren wirksame naphtochinon-verbindungen, zusammensetzungen und deren verwendungen
DE69402463T2 (de) (7S)-7-(2R)-2-(3-Chlorophenyl)-2-Hydoxyethylamino-5,6,7,8-Tetrahydronaphtalen-2-yloxy Essigsäure, ihre pharmazeutisch akzeptablen Salze, mit Beta-3-adrenergischer agonistischer Aktivität und diese enthaltende pharmazeutische Zusammensetzungen
DD210687A5 (de) Verfahren zur herstellung von (+)-cyanidan-3-ol-derivaten
JPS6251A (ja) シス，エンド−２−アザビシクロ〔３．３．０〕オクタン−３−カルボン酸誘導体およびその製法
US4540709A (en) Method for treatment of diseases mediated by PAF using 5-allyl-2-(3,4-Dimethoxyphenyl)-3a,α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran
DE4201942A1 (de) Phenonverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
CH629807A5 (de) Verfahren zur herstellung neuer substituierter purine.
KR20110135976A (ko) 산호 유래의 염증, 알레르기성 질환 치료약
DE4121468A1 (de) Antivirale substanzen und diese enthaltende arzneimittel
JP2011046734A (ja) セマフォリン阻害剤としての新規化合物
DE69824584T2 (de) Verwendung von diterpenen wie hypoestoxiden zur herstellung eines medikamentes zur immunsuppression, krebs- und antiviralen therapie
WO1991009595A1 (en) Anti-viral compositions
EP0289203B1 (en) Antitumor and antiviral compounds of marine origin
JPS5982375A (ja) ６−アニリノ−５，８−キノキサリンジオン類

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOLIPOX AB, SOLNA, SE

8328 Change in the person/name/address of the agent

Representative=s name: REHBERG HUEPPE + PARTNER, 37073 GOETTINGEN

R082 Change of representative

Ref document number: 1112262

Country of ref document: EP

Representative=s name: REHBERG HUEPPE + PARTNER, 37073 GOETTINGEN, DE